| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | -7.2B | -294% |
| Gross Profit | -2.1B | -288% |
| Cost Of Revenue | 2.3B | -9% |
| Operating Income | 272MM | -633% |
| Operating Expenses | -2.4B | - |
| Net Income | -2.2B | -186% |
| R&D | 172MM | +4% |
| G&A | 970MM | -3% |
| Amortization | 171MM | +6% |
| Interest Expense | 117MM | -14% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.
Comfort Systems USA and Boeing are part of the Zacks Bull and Bear of the Day article.
Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
DEERFIELD, Ill., April 11, 2024--Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, announced the continued expansion of its Pharmaceuticals portfolio with five injectable product launches in the U.S.
DEERFIELD, Ill., April 10, 2024--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2024 financial results on Thursday, May 2, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I215737 to pre-register for the call and receive the call information.
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.
The company is undergoing a transformation to a focused health care player
For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you...
Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.
DEERFIELD, Ill., April 01, 2024--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. Adding LVP modality to the Novum IQ Infusion Platform – which includes Baxter’s syringe infusion pump (SYR) with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite – enables clinicians to utiliz